Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdultAntibodies, Monoclonal, HumanizedChronic DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedMigraine DisordersOutcome Assessment, Health CareTime FactorsConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results